Category
Schedule 4
3 articles
Telehealth Prescribing of Schedule 4 Peptides in Australia: 2026 Policy Brief
Telehealth has become a permanent fixture of Australian healthcare. Its intersection with Schedule 4 peptide prescribing — covering agents like semaglutide, tirzepatide, and emerging research peptides — remains under-examined. This brief surveys the current regulatory framework, identifies oversight gaps, and proposes reform priorities to ensure clinical safety without restricting legitimate access.
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.
BPC-157 Schedule 4 in Australia: What the TGA Rescheduling Means and What Comes Next
A detailed policy and science analysis of Australia's TGA decision to reschedule BPC-157 to Schedule 4 in March 2025 — regulatory rationale, clinical implications, and the research evidence for this peptide.